cystic fibrosis

Oral specialty drug options on the horizon
Oral specialty drug options on the horizonAs more specialty drugs are approved, cost control strategies are key.
First patients enrolled in dry eye device studyPatient recruitment has started in a randomised clinical trial testing an experimental device (Lamelleye, known also as CXB/1-14) for the treatment of dry eye disease (DED).
FDA expands cystic fibrosis treatmentFDA expanded the use of ivacaftor (Kalydeco, Vertex Pharmaceuticals) to treat cystic fibrosis.
Asthma and kidney stones linked in childrenChildren with asthma are 4 times more likely to have kidney stones than those without asthma, and vice versa, according to a study published online in the medical journal PLoS One.
Cystic fibrosis guidelines for preschool childrenNew guidelines have been published that address monitoring cystic fibrosis in children aged between 2 and 5 years and highlight the key issues for pediatricians in caring for young children during this critical stage of development.
Better outcomes for CF patients in monitoring programStudy examines the effectiveness of the Walgreens Connected Care CF program compared to a matched sample of control patients.
Cystic fibrosis drug approved for younger patientsFDA recently expanded the use of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals) to treat cystic fibrosis in children aged 6 to 11 years who have two copies of the F508del mutation.
Genetic testing raises difficult questions for payersA new database helps payers understand which genetic tests are available, which genes they test for, and which tests would be appropriate to use to inform patient management.
Legally Speaking: Claim of failure to test for cystic fibrosisThis case emphasizes the importance of keeping detailed records of each patient encounter.
New cystic fibrosis drug has high potential, high costFDA’s approval of Vertex Pharmaceutical’s groundbreaking lumacaftor/ivacaftor (Orkambi) for cystic fibrosis (CF) is the first drug to treat the underlying cause of CF in people ages 12 and older with two copies of the F508del mutation.